<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151084</url>
  </required_header>
  <id_info>
    <org_study_id>BIL-MEK</org_study_id>
    <nct_id>NCT02151084</nct_id>
  </id_info>
  <brief_title>A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer</brief_title>
  <official_title>A Randomized Phase II Trial of MEK Inhibitor Selumetinib (AZD6244) Combined Continuously or Sequentially With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Patients With Advanced Biliary Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study (the second stage of testing a new drug or new drug combinations) to&#xD;
      see how useful two different schedules of study drug selumetinib with cisplatin and&#xD;
      gemcitabine are compared to cisplatin and gemticabine alone in patients with biliary cancer.&#xD;
&#xD;
      Selumetinib, an oral drug which plays an important role in the regulation of cell growth (MEK&#xD;
      1/2 inhibitor) has been shown to shrink tumours in patients with biliary cancer and other&#xD;
      types of human cancers. Selumetinib has also been shown to shrink tumours when given in&#xD;
      combination with cisplatin and gemcitabine in research studies done in animals and in some&#xD;
      patients with biliary tract cancer. Cisplatin and gemcitabine are intravenous drugs that work&#xD;
      by damaging DNA in tumor cells so that they are unable to grow and divide.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in tumor size in millimetres</measure>
    <time_frame>10 weeks post initiation of therapy</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective response and/or stable disease</measure>
    <time_frame>6 months post initiation of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients without progressive disease</measure>
    <time_frame>10 weeks post initiation of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival in months</measure>
    <time_frame>Enrollment to disease progression or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in months</measure>
    <time_frame>Time from enrollment to date of death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total incidence of adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total rate of grade 3 and 4 toxicities</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Biliary Tract Carcinoma</condition>
  <condition>Gallbladder Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A (Continuous Dosing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Run-In: Selumetinib, orally, BID for 7 days (Day -7 to Day -1)&#xD;
On treatment: Selumetinib, orally, BID from Day 1-21 of every 28 day cycle. Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Sequential Dosing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Run-In: Selumetinib, orally, BID for 5 days (Day -7 to Day -3) with 2 days washout&#xD;
On treatment: Selumetinib, orally, BID from Day 1-5 and 8-19 of every 28 day cycle.&#xD;
Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Standard Care)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selumetinib</intervention_name>
    <arm_group_label>Arm A (Continuous Dosing)</arm_group_label>
    <arm_group_label>Arm B (Sequential Dosing)</arm_group_label>
    <other_name>AZD6244</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Arm A (Continuous Dosing)</arm_group_label>
    <arm_group_label>Arm B (Sequential Dosing)</arm_group_label>
    <arm_group_label>Arm C (Standard Care)</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Arm A (Continuous Dosing)</arm_group_label>
    <arm_group_label>Arm B (Sequential Dosing)</arm_group_label>
    <arm_group_label>Arm C (Standard Care)</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Unresectable, recurrent or metastatic, measurable biliary tract cancer or gall bladder&#xD;
             cancer&#xD;
&#xD;
          -  No prior systemic therapy&#xD;
&#xD;
          -  Performance status 0, 1, or 2&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Estimated life expectancy &gt; 3 months&#xD;
&#xD;
          -  Adequate hematological, liver, renal function&#xD;
&#xD;
          -  No evidence of active uncontrolled infection&#xD;
&#xD;
          -  Capable of giving written consent&#xD;
&#xD;
          -  Acceptable recovery of previous side effects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Progressing within 3 or 6 months of receiving certain treatments&#xD;
&#xD;
          -  Prior chemotherapy for non-resectable or metastatic disease or a MEK inhibitor&#xD;
&#xD;
          -  Progressing within 6 months of adjuvant treatment.&#xD;
&#xD;
          -  May not have received prior chemotherapy for non-resectable/metastatic disease.&#xD;
&#xD;
          -  Prior MEK, RAS, or RAF inhibitors or history of hypersensitivity to study drugs.&#xD;
&#xD;
          -  Ampullary carcinoma&#xD;
&#xD;
          -  Incomplete recovery from previous surgery&#xD;
&#xD;
          -  Undergoing treatment with curative intent&#xD;
&#xD;
          -  Prior malignancy that could interfere with the response evaluation&#xD;
&#xD;
          -  Severe or uncontrolled systemic diseases or lab finding that makes it undesirable for&#xD;
             patient to participate&#xD;
&#xD;
          -  Any psychiatric or other disorder likely to impact consent&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Patients with significant cardiac-related issues&#xD;
&#xD;
          -  History of eye-related issues.&#xD;
&#xD;
          -  Systemic disease, active infection, bleeding diatheses or renal transplant, including&#xD;
             hep B, hep C or HIV&#xD;
&#xD;
          -  Receiving potent inhibitors or inducers of CYP3A4/5, CYP2C19 and CYP1A2 can continue&#xD;
             with caution&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Knox, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>randomized</keyword>
  <keyword>selumetinib</keyword>
  <keyword>tablets</keyword>
  <keyword>cisplatin</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>non-resectable</keyword>
  <keyword>recurrent</keyword>
  <keyword>metstatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

